Breaking News Instant updates and real-time market news.

MRK

Merck

$61.63

1.71 (2.85%)

, BMY

Bristol-Myers

$56.80

-3.18 (-5.30%)

06:07
01/12/17
01/12
06:07
01/12/17
06:07

Merck upgraded to Overweight from Neutral at Piper Jaffray

Piper Jaffray analyst Richard Purkiss upgraded Merck (MRK) to Overweight saying he expects the FDA will conditionally approve the use of Keytruda plus chemo by May 10. Keytruda's adoption in first-line lung cancer would then be "substantially brought forward" to the initial detriment of Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY), Purkiss tells investors in a research note. The earlier than expected boost to Keytruda sales increases the analyst's 2017-2019 earnings forecasts for Merck by 12%-18%. Purkiss raised his price target for the shares to $72 from $63. The stock closed yesterday up $1.71 to $61.63.

MRK

Merck

$61.63

1.71 (2.85%)

BMY

Bristol-Myers

$56.80

-3.18 (-5.30%)

AZN

AstraZeneca

$28.18

-0.57 (-1.98%)

RHHBY

Roche

$29.48

-0.51 (-1.70%)

  • 19

    Jan

  • 26

    Jan

  • 01

    Feb

  • 02

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 15

    Mar

  • 10

    May

  • 27

    May

MRK Merck
$61.63

1.71 (2.85%)

01/11/17
BMOC
01/11/17
NO CHANGE
BMOC
FDA decision a significant boost for Merck, says BMO Capital
BMO Capital analyst Alex Arfaei says that the FDA's acceptance and priority review of Merck's Keytruda+chemo in first line non-small cell lung cancer "is a positive surprise." and "represents significant upside" for the company. The analyst thinks that Keytruda's market share in first line non-small cell lung cancer can reach about 80%-85%, up from about 25% now. He continues to identify Merck as his top pick.
01/11/17
JEFF
01/11/17
NO CHANGE
Target $48
JEFF
Buy
Merck filing for Keytruda could disrupt market, says Jefferies
Jefferies analyst Jeffrey Holford views Merck's (MRK) filing for Keytruda plus chemo in first line non-small cell lung cancer as a "positive surprise" that could disrupt market share dynamics in the near term, particularly for Bristol-Myers (BMY). The filing, however, does not materially change Merck's long term outlook, Holford tells investors in a research note. He believes approval risk is high given limited data and keeps an Underperform rating on Merck. The stock is up $1.78 to $61.70 in pre-market trading while Bristol-Myers is down $1.98 to $58.00.
01/11/17
JPMS
01/11/17
NO CHANGE
JPMS
Overweight
Keytruda filing a 'distinct positive' for Merck, says JPMorgan
JPMorgan analyst Chris Schott views the acceptance of the Keytruda plus chemo combo supplementary Biologics License Application for priority review as a "distinct positive" for Merck (MRK). The company is increasingly well positioned in first-line lung cancer, Schott tells investors in a research note. The analyst reiterates an Overweight rating on Merck.
01/11/17
GSCO
01/11/17
NO CHANGE
Target $70
GSCO
Neutral
Goldman sees Merck advantage for Keytruda in first-line NSCLC to be short-lived
Goldman Sachs analyst Jami Rubin said that if Merck's (MRK) chemo combo sBLA is approved, she would expect a "rapid uptake" for Keytruda in the first-line setting given there will be no requirement for PD-L1 testing. However, while Merck may benefit in the near-term in 2017, she is making no change to her 2018 estimates given imminent competition from potentially three other players, adding that she is also making no changes to her estimates for Bristol-Myers (BMY) as she has estimates for first-line non-small cell lung cancer only from 2018. Rubin maintains her Neutral rating and $70 price target on Merck shares.
BMY Bristol-Myers
$56.80

-3.18 (-5.30%)

12/19/16
12/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) and Bayer (BAYRY) were upgraded to Buy from Hold at Jefferies. 2. Costco (COST) upgraded to Buy from Neutral at Citi with analyst Kate McShane saying she sees a "clear path" to accelerating same-store-sales growth in fiscal 2017 as gasoline price deflation headwinds abate and benefits arise from the new co-branded credit card. 3. United Technologies (UTX) upgraded to Outperform from Neutral at Credit Suisse with analyst Julian Mitchell saying he believes consensus estimates are poised to move higher after years of heavy investment spending drive an earnings recovery. 4. ASML (ASML) upgraded to Buy from Neutral at BofA/Merrill with analyst Kai Korschelt saying a recent expert's call indicates progress with Extreme Ultraviolet/EUV lightsource optics & ecosystem and sees improving volume visibility from 2018 forward. 5. Gulfport Energy (GPOR) upgraded to Buy from Neutral at Guggenheim and to Overweight from Equal Weight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/16
JEFF
12/19/16
DOWNGRADE
Target $48
JEFF
Underperform
Merck downgraded to Underperform from Hold at Jefferies
Jefferies analyst Jeffrey Holford downgraded Merck (MRK) to Underperform, his firm's sell-rating equivalent. The analyst sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. Potential dual eligible rebate reform is the most significant risk, Holford tells investors in a research note. Specific to Merck, the analyst expects further pressure on Keytruda in 2018, driven by share losses in non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY). Merck screens poorly on many valuation metrics, Holford contends. He lowered his price target for the shares to $48 from $59. The stock closed Friday up 7c to $62.44. The analyst this morning also upgraded both Bristol-Myers Squibb (BMY) and Bayer (BAYRY) to Buy from Hold. His top picks in Pharmaceuticals are AbbVie (ABBV) and Eli Lilly (LLY) for the U.S. and AstraZeneca and Novartis (NVS) in Europe.
AZN AstraZeneca
$28.18

-0.57 (-1.98%)

12/20/16
SBSH
12/20/16
NO CHANGE
Target $151
SBSH
Buy
Citi views Rubraca approval as positive for PARP class
Citi analyst Robyn Karnauskas views the approval of Clovis Oncology's (CLVS) Rubraca as positive for the PARP class. She keeps a Buy rating on TESARO (TSRO) with a $151 price target. TESARO's Niraparib is expected to be approved for second-line maintenance in 2017 while data from its third-line study are expected in the second half of the year. The analyst currently assigns a50% probability to Niraparib in third-line line and 35% market share. Karnauskas notes that Rubraca costs $13,740 for 30 days, below AstraZeneca's (AZN) Lynparza's $11,984. Her model assumes monthly pricing of $10,000 for Niraparib.
12/20/16
LEER
12/20/16
NO CHANGE
LEER
Outperform
Clovis Rubraca approval unlikely to impact TESARO niraparib, says Leerink
Commenting on Clovis' (CLVS) Rubraca accelerated approval by the FDA for the treatment of germline or somatic BRCA-mutated ovarian cancer patients, Leerink analyst Seamus Fernandez says the label appears "fairly broad" and does not restrict use based on platinum sensitivity/resistance. While he believes this current approval is unlikely to impact the initial competitive dynamics for TESARO's (TSRO) niraparib or AstraZeneca's (AZN) Lynparza in second-line maintenance, the analyst points out that data from Rubraca's Phase 3 ARIEL3 trial in this setting is now expected in mid-2017. Despite the earlier readout, Fernandez continues to see niraparib as the ultimate winner in second-line maintenance. He reiterates an Outperform rating on TESARO's shares.
12/19/16
JEFF
12/19/16
UPGRADE
Target $69
JEFF
Buy
Bristol-Myers upgraded to Buy from Hold at Jefferies
Jefferies analyst Jeffrey Holford upgraded Bristol-Myers Squibb (BMY) to Buy on expectations the company will share with AstraZeneca (AZN) the cytotoxic T-lymphocyte-associated antigen-4 combo opportunity in non-small cell lung cancer. Holford views Bristol shares as attractive valued and upped his price target for the name to $69 from $60.
RHHBY Roche
$29.48

-0.51 (-1.70%)

12/15/16
CANT
12/15/16
NO CHANGE
Target $8
CANT
Overweight
Pacific Biosciences a 'viable takeout target,' says Cantor
Cantor analyst Bryan Brokmeier says Pacific Biosciences' (PACB) shares are oversold after the company announced that Roche (RHHBY) has terminated their IVD-distribution agreement, whereby Roche had exclusive distribution rights of the Sequel into the clinical market. While the analyst acknowledges Roche's termination of the agreement is a clear long-term strategic negative, he says it is not nearly as much as the stock selloff is implying and notes that Pacific Biosciences is now positioned to sell into the clinical sequencing market directly or through other partners. Moreover, Brokmeier believes Pacific Biosciences is now "effectively a viable takeout target" for other companies, with Agilent (A), Bio-Techne (TECH), Illumina (ILMN), PerkinElmer (PKI), Thermo Fisher (TMO), and Roche among potential acquirers. He reiterated an Overweight rating on Pacific Biosciences' stock, but lowered his price target on the shares to $8 from $15.
01/03/17
RAJA
01/03/17
NO CHANGE
RAJA
Drug price hikes continue unabated, says Raymond James
In a research note titled "Think the Era of Drug Price Increases is Over? Think Again.," Raymond James analyst Christopher Raymond says drug price increases in 2017 are continuing unabated. According to Wolters Kluwer Health, January 1 saw a "sizeable amount of key biotech drug price increases," Raymond tells investors. The price hikes look in-line with previous patterns, or - in the case of Biogen (BIIB) - "measurably more aggressive than norm," the analyst contends. Of the names he follows, Biogen, Acorda Therapeutics (ACOR) and AMAG Pharmaceuticals (AMAG) implemented increases. Raymond also highlights AstraZeneca's (AZN) 5% Lynparza increase and Roche's (RHHBY) "slew of increases" with Actemra up 1.5%, Herceptin up 3%, Pegasys up 5%.
01/03/17
LEER
01/03/17
NO CHANGE
Target $20
LEER
Outperform
Leerink remains bullish on Exelixis in 2017
Leerink analyst Michael Schmidt remains bullish on Exelixis in 2017 and expects continued strong U.S. sales growth of Cabometyx in renal cell carcinoma while several label extension opportunities as well as Roche's (RHHBY) IO strategy for Cotellic are key sources of upside to the current valuation. The analyst reiterated an Outperform rating on Exelixis' stock and raised his price target on the shares to $20 from $16 to reflect his more bullish stance on Cabometyx label extension opportunities, as well as incrementally higher Cotellic profit share estimates following recently announced plans by Roche to initiate additional Phase 3 trials.

TODAY'S FREE FLY STORIES

21:00
05/26/17
05/26
21:00
05/26/17
21:00
General news
Breaking General news story  »

San Francisco Federal…

20:00
05/26/17
05/26
20:00
05/26/17
20:00
General news
Breaking General news story  »

San Francisco Federal…

JUNO

Juno Therapeutics

$23.30

-2.22 (-8.70%)

18:11
05/26/17
05/26
18:11
05/26/17
18:11
Hot Stocks
Juno Therapeutics director acquires 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

18:06
05/26/17
05/26
18:06
05/26/17
18:06
Hot Stocks
UnitedHealth's OptumHealth awarded $200.5M government contract »

UnitedHealth's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

VEC

Vectrus

$29.62

0.02 (0.07%)

17:56
05/26/17
05/26
17:56
05/26/17
17:56
Hot Stocks
Vectrus Systems awarded $212.03M modification to government contract »

Vectrus Systems was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMY

Imprimis

$3.34

-0.06 (-1.76%)

17:52
05/26/17
05/26
17:52
05/26/17
17:52
Syndicate
Breaking Syndicate news story on Imprimis »

Imprimis files $75M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRCP

IRSA Propiedades Comerciales

$43.58

-0.33 (-0.75%)

17:51
05/26/17
05/26
17:51
05/26/17
17:51
Syndicate
Breaking Syndicate news story on IRSA Propiedades Comerciales »

IRSA Propiedades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSKE

Daseke

$9.79

-0.11 (-1.11%)

17:44
05/26/17
05/26
17:44
05/26/17
17:44
Syndicate
Breaking Syndicate news story on Daseke »

Daseke files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECYT

Endocyte

$2.47

0.02 (0.82%)

, RNN

Rexahn

$4.04

0.09 (2.28%)

17:35
05/26/17
05/26
17:35
05/26/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Endocyte (ECYT),…

ECYT

Endocyte

$2.47

0.02 (0.82%)

RNN

Rexahn

$4.04

0.09 (2.28%)

TGTX

TG Therapeutics

$12.05

0.15 (1.26%)

SGMO

Sangamo

$7.25

-0.55 (-7.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 22

    Jun

ECYT

Endocyte

$2.47

0.02 (0.82%)

17:33
05/26/17
05/26
17:33
05/26/17
17:33
Hot Stocks
Endocyte to announce updated data on EC1456, EC1169 at ASCO »

Endocyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

PEP

PepsiCo

$117.91

0.38 (0.32%)

17:30
05/26/17
05/26
17:30
05/26/17
17:30
Periodicals
PepsiCo in talks to acquire Vita Coco owner All Market, Reuters reports »

PepsiCo is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCOV

Brightcove

$6.25

0.25 (4.17%)

17:25
05/26/17
05/26
17:25
05/26/17
17:25
Hot Stocks
Breaking Hot Stocks news story on Brightcove »

ESW Capital reports 8.08%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

SHIP

Seanergy Marine

$0.69

0.001244 (0.18%)

17:19
05/26/17
05/26
17:19
05/26/17
17:19
Hot Stocks
Seanergy Marine receives Nasdaq notice »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.93

0.07 (0.64%)

, DB

Deutsche Bank

$18.46

-0.39 (-2.07%)

17:10
05/26/17
05/26
17:10
05/26/17
17:10
General news
S&P advances to end week at record as Fed signals no rush to normalize policy »

The S&P 500 (SPX)…

F

Ford

$10.93

0.07 (0.64%)

DB

Deutsche Bank

$18.46

-0.39 (-2.07%)

BBY

Best Buy

$58.97

-2.28 (-3.72%)

HPQ

HP Inc.

$18.47

0.1 (0.54%)

BX

Blackstone

$32.58

0.11 (0.34%)

NOK

Nokia

$6.38

-0.02 (-0.31%)

AAPL

Apple

$153.61

-0.26 (-0.17%)

GM

General Motors

$33.07

0.47 (1.44%)

HUN

Huntsman

$24.75

-0.11 (-0.44%)

BF.A

Brown-Forman, also tag with BFA, BFB

$52.49

-0.21 (-0.40%)

BF.B

Brown-Forman, also tag with BFA, BFB

$51.73

0.13 (0.25%)

STZ

Constellation Brands

$180.93

0.79 (0.44%)

LOW

Lowe's

$80.91

-0.42 (-0.52%)

TIF

Tiffany

$86.18

0.36 (0.42%)

SHLD

Sears

$7.78

-0.7 (-8.25%)

SIG

Signet Jewelers

$49.31

-0.99 (-1.97%)

COST

Costco

$177.86

3.13 (1.79%)

ANF

Abercrombie & Fitch

$13.22

-0.83 (-5.91%)

AEO

American Eagle

$11.50

0.08 (0.70%)

EXPR

Express

$7.85

0.03 (0.38%)

TTWO

Take-Two

$77.07

-1.46 (-1.86%)

AZO

AutoZone

$615.62

8.28 (1.36%)

DSW

DSW

$16.73

-0.06 (-0.36%)

INTU

Intuit

$138.56

0.2 (0.14%)

PBYI

Puma Biotechnology

$79.75

1.7 (2.18%)

CHS

Chico's

$9.37

-0.39 (-4.00%)

SPLS

Staples

$8.98

-0.08 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 31

    May

  • 31

    May

  • 01

    Jun

  • 01

    Jun

  • 01

    Jun

  • 02

    Jun

  • 06

    Jun

  • 06

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 20

    Jun

  • 28

    Jun

  • 21

    Jul

BGNE

BeiGene

$37.42

-0.04 (-0.11%)

17:07
05/26/17
05/26
17:07
05/26/17
17:07
Syndicate
Breaking Syndicate news story on BeiGene »

BeiGene files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 06

    Jun

CGI

Celadon Group

17:06
05/26/17
05/26
17:06
05/26/17
17:06
Hot Stocks
Breaking Hot Stocks news story on Celadon Group »

Litespeed Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRD

Crawford & Company Inc.

, CRDA

Crawford & Co.

$7.65

0.01 (0.13%)

17:05
05/26/17
05/26
17:05
05/26/17
17:05
Hot Stocks
Crawford & Company COO Robinson to leave company »

Crawford & Company…

CRD

Crawford & Company Inc.

CRDA

Crawford & Co.

$7.65

0.01 (0.13%)

CRDB

Crawford & Company

$9.08

-0.02 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEAS

SeaWorld

$18.08

-0.13 (-0.71%)

17:03
05/26/17
05/26
17:03
05/26/17
17:03
Hot Stocks
Breaking Hot Stocks news story on SeaWorld »

Hill Path Capital raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMRC

Digimarc

$36.10

2.45 (7.28%)

17:03
05/26/17
05/26
17:03
05/26/17
17:03
Syndicate
Breaking Syndicate news story on Digimarc »

Digimarc files $100M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 06

    Sep

IPCI

Intellipharmaceutics

$1.94

-0.01 (-0.51%)

17:01
05/26/17
05/26
17:01
05/26/17
17:01
Syndicate
Breaking Syndicate news story on Intellipharmaceutics »

Intellipharmaceutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GWR

Genesee & Wyoming

$66.47

0.91 (1.39%)

16:57
05/26/17
05/26
16:57
05/26/17
16:57
Hot Stocks
Genesee & Wyoming CEO Hellmann named chairman of the board »

Genesee & Wyoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZG

Paramount Gold Nevada

$1.61

0.02 (1.26%)

16:54
05/26/17
05/26
16:54
05/26/17
16:54
Syndicate
Breaking Syndicate news story on Paramount Gold Nevada »

Paramount Gold Nevada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMO

Sangamo

$7.25

-0.55 (-7.05%)

16:53
05/26/17
05/26
16:53
05/26/17
16:53
Syndicate
Breaking Syndicate news story on Sangamo »

Sangamo files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

TGTX

TG Therapeutics

$12.05

0.15 (1.26%)

16:49
05/26/17
05/26
16:49
05/26/17
16:49
Syndicate
Breaking Syndicate news story on TG Therapeutics »

TG Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 22

    Jun

AVXL

Anavex

$5.88

-0.06 (-1.01%)

16:49
05/26/17
05/26
16:49
05/26/17
16:49
Syndicate
Breaking Syndicate news story on Anavex »

Anavex files to sell 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.